Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: A systematic review and network meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 1, 2018, Pages 22-32

  Kengkla, Kirati ^a   Kongpakwattana, Khachen ^b   Saokaew, Surasak ^a,b,c   Apisarnthanarak, Anucha ^d   Chaiyakunapruk, Nathorn ^b,c,e  

^a UNIVERSITY OF PHAYAO   (Thailand)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c NARESUAN UNIVERSITY   (Thailand)

^d THAMMASAT UNIVERSITY   (Thailand)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; COLISTIN; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER INFECTION; ALL CAUSE MORTALITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOODSTREAM INFECTION; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EXTENSIVELY DRUG RESISTANCE; HUMAN; META ANALYSIS; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NETWORK META-ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER BAUMANNII; ANALOGS AND DERIVATIVES; DRUG EFFECT; FEMALE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; SULBACTAM; TREATMENT OUTCOME;

EID: 85040623335     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx368     Document Type: Article

References (66)

1. Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-84
2. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23: 332-9
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82
4. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14
5. Lemos EV, de la Hoz FP, Einarson TR et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic reviewandmeta-analysis. Clin Microbiol Infect 2014; 20: 416-23
6. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003; 36: 1111-8
7. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenemresistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74: 1315-33
8. Chen Z, Chen Y, Fang Y et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 2015; 5: 8
9. Corbella X, Ariza J, Ardanuy C et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793-802
10. Dong X, Chen F, Zhang Y et al. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.JAntibiot (Tokyo) 2014; 67: 677-80
11. KempfM, Djouhri-Bouktab L, Brunel JM et al. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012; 39: 180-1
12. Ni W, Han Y, Zhao J et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review andmeta-analysis. Int J Antimicrob Agents 2016; 47: 107-16
13. ChuH, Zhao L,WangMet al. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 2013; 17: 389-94
14. Liu Q, Li W, Feng Y et al. Efficacy and safety of polymyxins for the treatment of Acinetobacter baumannii infection: a systematic review and metaanalysis. PLoS One 2014; 9: e98091
15. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-24
16. Chaiyakunapruk N, Kengkla K, Apisarnthanarak A et al. Comparative Efficacy and Safety Of Therapeutic Options for Multidrug-resistant Acinetobacter Baumannii (MDR-AB) Infections: A Systematic Review and Network Meta-analysis. 2016. http://www.crd.york.ac.uk/PROSPERO/display_ record.asp?ID"CRD42016042494
17. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network metaanalyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-84
18. Kalil AC, Metersky ML, Klompas M et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61-e111
19. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.AmJ Infect Control 2008; 36: 309-32
20. Cameron C, Fireman B, Hutton B et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev 2015; 4: 147
21. Teerawattanapong N, Kengkla K, Dilokthornsakul P et al. Prevention and control of multidrug-resistant gram-negative bacteria in adult intensive care units: a systematic review and network meta-analysis. Clin Infect Dis 2017; 64: S51-60
22. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://handbook-5-1.cochrane.org
23. Sterne JA, Hernan MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
24. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. NephronClinPract 2012; 120: c179-84
25. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
27. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60
28. Chaimani A, Higgins JP, Mavridis D et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013; 8: e76654
29. White IR. Networkmeta-analysis. Stata J 2015; 15: 951-85
30. Lu G, Ades AE. Combination of direct and indirect evidence inmixed treatment comparisons. Stat Med 2004; 23: 3105-24
31. Veroniki AA, Vasiliadis HS, Higgins JP et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013; 42: 332-45
32. Higgins JP, Jackson D, Barrett JK et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012; 3: 98-110
33. Dias S,Welton NJ, Caldwell DMet al. Checking consistency inmixed treatment comparisonmeta-analysis. Stat Med 2010; 29: 932-44
34. Salanti G, Ades AE, Ioannidis JP. Graphicalmethods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163-71
35. Dechartres A, Altman DG, Trinquart L et al. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 2014; 312: 623-30
36. Lee CM, Lim HK, Liu CP et al. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005; 37: 195-9
37. Holloway KP, Rouphael NG, Wells JB et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006; 40: 1939-45
38. Betrosian AP, Frantzeskaki F, Xanthaki A et al. High-dose ampicillinsulbactam as an alternative treatment of late-onset VAP from multidrugresistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39: 38-43
39. Gounden R, Bamford C, van Zyl-Smit R et al. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009; 9: 6
40. Jang JJ, Kim MN, Lee K et al. The comparative efficacy of colistin monotherapy and combination therapy based on in vitro antimicrobial synergy in ventilator-associated pneumonia caused by multi-drug resistant Acinetobacter baumannii. Tuberc Respir Dis 2009; 67: 212-20
41. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilatorassociated pneumonia. J IntensiveCareMed2010; 25: 343-8
42. Nakwan N, Wannaro J, Thongmak T et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol 2011; 46: 60-6
43. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva 2011; 35: 226-31
44. TasbakanMS, Pullukcu H, Sipahi OR et al. Is tigecyclinagoodchoice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? JChemother 2011; 23: 345-9
45. Kalin G, Alp E, Coskun R et al. Use of high-dose IV and aerosolized colistin for the treatment ofmultidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia: dowe really need this treatment? J Infect Chemother 2012; 18: 872-7
46. Shields RK, Clancy CJ, Gillis LM et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012; 7: e52349
47. Shin JA, Chang YS, Kim HJ et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J 2012; 53: 974-84
48. Aydemir H, Akduman D, Piskin N et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141: 1214-22
49. Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349-58
50. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013; 59: 225-31
51. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2013; 32: 1211-20
52. Batirel A, Balkan II, Karabay O et al. Comparison of colistincarbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33: 1311-22
53. Chuang YC, Cheng CY, Sheng WHet al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 2014; 14: 102
54. Kalin G, Alp E, Akin A et al. Comparison of colistin and colistin/sulbactam for the treatment ofmultidrug resistant Acinetobacter baumannii ventilatorassociated pneumonia. Infection 2014; 42: 37-42
55. Khawcharoenporn T, Pruetpongpun N, Tiamsak P et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 2014; 43: 378-82
56. Kwon SH, AhnHL, HanOY et al. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull 2014; 37: 340-6
57. López-Cortés LE, Cisneros JM, Fernández-Cuenca F et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014; 69: 3119-26
58. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58: 5598-601
59. Cheng A, Chuang YC, Sun HY et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 2015; 43: 1194-204
60. Jean SS, Hsieh TC, Hsu CW et al. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. J Microbiol Immunol Infect 2016; 49: 924-33
61. Yilmaz GR, Guven T, Guner R et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015; 9: 476-85
62. Kim WY, Moon JY, Huh JW et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drugresistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One 2016; 11: e0150642
63. Zalts R, Neuberger A, Hussein K et al. Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. AmJ Ther 2016; 23: e78-85
64. Wei W, Yang H, Liu Y et al. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase.J Chemother 2016; 28: 159-63
65. FanB,Guan J,Wang X et al. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thighinfectionmodel. PLoS One 2016; 11: e0157757
66. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol 2011; 7: 1459-70